Printer Friendly

WATSON PHARMACEUTICALS ANNOUNCES FDA APPROVAL FOR ALBUTEROL SYRUP

 CORONA, Calif., May 4 /PRNewswire/ -- Watson Pharmaceuticals (NASDAQ: WATS) today announced that it has received approval from the Food and Drug Administration (FDA) for an off-patent syrup form of Albuterol Sulfate 2mg/5ml. Albuterol Sulfate is used in the treatment of bronchial asthma.
 According to Dr. Allen Chao, president and chief executive officer, Albuterol Sulfate Syrup will be competitive with Proventil(R) and Ventolin(R), in a market which is estimated at $35 million. The company expects to begin marketing the product after pre-shipment validation requirements are met.
 "While we are the second off-patent drug manufacturer to receive FDA approval for Albuterol Sulfate Syrup, the company is optimistic that the product will contribute positively to earnings of the company," noted Chao.
 Watson Pharmaceuticals manufactures and distributes off-patent pharmaceuticals and is developing advanced drug delivery systems designed to enhance the therapeutic benefits of pharmaceutical compounds.
 -0- 5/4/93
 /CONTACT: Doug Sherk, Ken Dennard or Stuart Brunet, 415-296-7383, or June Filingeri or Miriam Adler, 212-986-5900, all of Morgen-Walke, for Watson Pharmaceuticals/
 (WATS)


CO: Watson Pharmaceuticals ST: California IN: MTC SU:

ML-GT -- SF003 -- 4087 05/04/93 06:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1993
Words:188
Previous Article:DELL PROMOTES EXECUTIVE TO LEAD SALES, MARKETING & SERVICES WORLDWIDE
Next Article:READER'S DIGEST REPORTS RECORD REVENUES, PROFITS FOR FISCAL 1993 THIRD QUARTER AND NINE MONTHS
Topics:


Related Articles
COMMUNITY MUTUAL AIDING IN DRUG RECALL MANDATED BY THE FDA
COPLEY PHARMACEUTICAL REPORTS ON INVESTIGATION OF ASTHMA PRODUCT RECALL
COPLEY PHARMACEUTICAL REPORTS ON INVESTIGATION OF ASTHMA PRODUCT RECALL
PHARMACEUTICAL RESOURCES SIGNS DISTRIBUTION AGREEMENT WITH MOVA FOR TWO PRODUCTS
PHARMACEUTICAL RESOURCES SIGNS DISTRIBUTION AGREEMENT WITH MOVA FOR TWO PRODUCTS
SCHERING-PLOUGH SEES STRONG PERFORMANCE IN 1996 DESPITE GENERIC ALBUTEROL MDI APPROVAL
Watson Pharmaceuticals, Inc. Announces Receipt of Approvable Letter for First NDA Product: Microzide(TM) (Hydrochlorothiazide) 12.5 MG Capsules
Alpharma USPD Announces FDA Approval of Cromolyn Sodium Inhalation Solution USP.
Watson Receives FDA Approval for Generic Accuneb(R).
Watson Receives FDA Approval for Generic DuoNeb(R).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters